Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 52, Issue 4, 2008, Pages 441-454

  Khan, Mazhar U ^a   Morse, M ^a   Coleman, R E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

3 Iodobenzylguanidine; Carcinoid tumor; Carcinoid tumor, therapy; Diagnosis

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 124; (3 IODOBENZYL)GUANIDINE I 131; ANGIOPEPTIN; BEVACIZUMAB; BIOCHEMICAL MARKER; CAPECITABINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; IMATINIB; OCTREOTIDE; PACLITAXEL; PEGINTERFERON ALPHA2B; PENTETATE INDIUM IN 111; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

5 HYDROXYINDOLEACETIC ACID BRAIN LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CARCINOID; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; DRUG UPTAKE; ERYTHROCYTE COUNT; FATIGUE; HUMAN; IMAGE QUALITY; ISOTOPE LABELING; LEUKOCYTE COUNT; MOLECULAR IMAGING; NAUSEA; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAROTID GLAND DISEASE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; SEROTONIN BLOOD LEVEL; SEROTONIN RELEASE; SIDE EFFECT; SYSTEMIC THERAPY; TASTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING; WEIRD SENSATION; XEROSTOMIA;

3-IODOBENZYLGUANIDINE; ANIMALS; CARCINOID TUMOR; HUMANS; IODINE RADIOISOTOPES; SOMATOSTATIN;

EID: 60549088531     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Lubarsch O. Ueber den primären Krebs des Ileum, nebst Bemerkungen über das gleichzeitige Vorkommen von Krebs und Tuberkolose. Virchows Arch 1888;111:280-317.
2. Godwin JD, 2nd. Carcinoid tumors. An analysis of 2,837 cases. Cancer 1975;36:560-9.
3. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79:813-29.
4. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999;340:858-68.
5. Berge T, Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand [A] 1976;84:322-30.
6. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-59.
7. Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol 2004;43:617-25.
8. Stroosma OB, Delaere KP. Carcinoid tumours of the testis. BJU Int 2008;101:1101-5.
9. Zehlicke T, Punke C, Boltze C, Pau HW. Transient facial palsy in two cases of benign, very rare middle ear tumors (carcinoid tumor and myxoma). Neurologist 2008;14:52-5.
10. Mufarrij P, Varkarakis IM, Studeman KD, Jarrett TW. Primary renal carcinoid tumor with liver metastases detected with somatostatin receptor imaging. Urology 2005;65:1002.
11. Horton KM, Kamel I, Hofmann L, Fishman EK. Carcinoid tumors of the small bowel: a multitechnique imaging approach. AJR Am J Roentgenol 2004;182:559-67.
12. Picus D, Glazer HS, Levitt RG, Husband JE. Computed tomography of abdominal carcinoid tumors. AJR Am J Roentgenol 1984;143:581-4.
13. Tamm EP, Kim EE, Ng CS. Imaging of neuroendocrine tumors. Hematol Oncol Clin North Am 2007;21:409-32; vii.
14. Woodard PK, Feldman JM, Paine SS, Baker ME. Midgut carcinoid tumors: CT findings and biochemical profiles. J Comput Assist Tomogr 1995;19:400-5.
15. Sugimoto E, Lorelius LE, Eriksson B, Oberg K. Midgut carcinoid tumours. CT appearance. Acta Radiol 1995;36:367-71.
16. Oberg K, Eriksson B. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab 2005;19:265-76.
17. Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog. J Steroid Biochem Mol Biol 1990;37: 1079-82.
18. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001; 86:895-902.
19. Kvols LK, Brown ML, O'Connor MK, Hung JC, Hayostek RJ, Reubi JC et al. Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology 1993;187:129-33.
20. Schillaci O, Scopinaro F, Angeletti S, Tavolaro R, Danieli R, Annibale B et al. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. J Nucl Med 1996;37:1452-6.
21. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998;25:79-83.
22. 18F-FDG. Cancer 2008;112:2447-55.
23. 131I]iodobenzylguanidine. J Nucl Med 1980;21:349-53.
24. Hoefnagel CA, den Hartog Jager FC, Taal BG, Abeling NG, Engelsman EE. The role of I-131-MIBG in the diagnosis and therapy of carcinoids. Eur J Nucl Med 1987;13:187-91.
25. Feldman JM, Blinder RA, Lucas KJ, Coleman RE. Iodine-131 metaiodobenzylguanidine scintigraphy of carcinoid tumors. J Nucl Med 1986;27:1691-6.
26. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005;128:1717-51.
27. Le Rest C, Bomanji JB, Costa DC, Townsend CE, Visvikis D, Ell PJ. Functional imaging of malignant paragangliomas and carcinoid tumours. Eur J Nucl Med 2001;28:478-82.
28. Zuetenhorst JM, Hoefnageli CA, Boot H, Valdes Olmos RA, Taal BG. Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002;23:735-41.
29. Hanson MW, Feldman JM, Blinder RA, Moore JO, Coleman RE. Carcinoid tumors: iodine-131 MIBG scintigraphy. Radiology 1989;172:699-703.
30. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004;151: 15-27.
31. Carnaille B, Nocaudie M, Pattou F, Huglo D, Deveaux M, Marchandise X et al. Scintiscans and carcinoid tumors. Surgery 1994;116:1118-21; discussion 21-2.
32. 111In-pentetreotide in carcinoid tumours. Eur J Cancer 1996; 32A: 1924-32.
33. Nocaudie-Calzada M, Huglo D, Carnaille B, Proye C, Marchandise X. Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours. Eur J Nucl Med 1996;23:1448-54.
34. Bomanji J, Mather S, Moyes J, Ellison D, Grossman A, Britton KE et al. A scintigraphic comparison of iodine-123-metaiodobenzylguanidine and an iodine-labeled somatostatin analog (Tyr-3-octreotide) in metastatic carcinoid tumors. J Nucl Med 1992;33: 1121-4.
35. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004;25:458-511.
36. 124I-mIBG positron emission tomography. Br J Radiol 1992; 65:787-91.
37. Prvulovich EM, Stein RC, Bomanji JB, Ledermann JA, Taylor I, Ell FJ. Iodine-131-MIBG therapy of a patient with carcinoid liver metastases. J Nucl Med 1998;39:1743-5.
38. Hoefnagel CA, Den Hartog Jager FC, Van Gennip AH, Marcuse HR, Taal BG. Diagnosis and treatment of a carcinoid tumor using iodine-131 meta-iodobenzylguanidine. Clin Nucl Med 1986;11:150-2.
39. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J et al. Treatment of metastatic carcinoid turnouts, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol (Oxf) 2001;55:47-60.
40. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman J, Onaitis MW et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 2004;101:1987-93.
41. Pathirana AA, Vinjamuri S, Byrne C, Ghanch P, Vora J, Poston GJ. (131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. Eur J Surg Oncol 2001;27:404-8.
42. Vaidyanathan G, Affleck DJ, Zalutsky MR. No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue. Appl Radiat Isot 2005;62:435-40.
43. Fullerton NE, Boyd M, Ross SC, Pimlott SL, Babich J, Kirk D et al. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MlBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma. Med Chem 2005;1:611-8.
44. Mairs RJ, Ross SC, McCluskey AG, Boyd M. A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo. J Nucl Med 2007;48:1519-26.
45. Knickmeier M, Matheja P, Wichter T, Schafers KP, Kies P, Breithardt G et al. Clinical evaluation of no-carrier-added meta-[123I]iodobenzylguanidine for myocardial scintigraphy. Eur J Nucl Med 2000;27:302-7.
46. Leong WL, Pasieka JL. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol 2002;79:180-7.
47. Nilsson O, Kolby L, Wangberg B, Wigander A, Billig H, William-Olsson L et al. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 1998;77:632-7.
48. Garland J, Buscombe JR, Bouvier C, Bouloux P, Chapman MH, Chow AC et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003;17:437-44.
49. Ruszniewski P, Ducreux M, Chayvialle JA, Blumberg J, Cloarec D, Michel H et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996;39:279-83.
50. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptomns. J Clin Oncol 1999; 17: 1111.
51. Ricci S, Antonuzzo A, Galli L, Orlandini C, Ferdeghini M, Boni G et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000;23:412-5.
52. Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000;95:3276-81.
53. Schnirer, II, Yao JC, Ajani JA. Carcinoid - a comprehensive review. Acta Oncol 2003;42:672-92.
54. Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993;32:225-9.
55. Frank M, Klose EJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999;94:1381-7.
56. Oberg K. Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol 1993;5:110-20.
57. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002;32:133-40.
58. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002;32:123-32.
59. 111in-pentetreotide: initial observations and future directions. Cancer J Sci Am 1998;4:94-102.
60. De Jong M, Breeman WA, Bernard HF, Kooij PP, Slooter GD, Van Eijck CH et al. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. Q J Nucl Med 1999;43:356-66.
61. 111In-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003;44:1-6.
62. Lewington VJ. Targeted radionuclide therapy for neuroendocrine tumours. Endocr Relat Cancer 2003;10:497-501.
63. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26:1439-47.
64. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148-55.
65. 90Y-labeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:13S-7S.
66. Bukowski RM, Tangen CM, Peterson RF, Taylor SA, Rinehart JJ, Eyre HJ et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer 1994;73:1505-8.
67. Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001;12:1139-43.
68. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005;23:4897-904.
69. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-91.
70. Kulke MH, Kim H, Clark JW, Enzinger PC, Lynch TJ, Morgan JA et al. A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 2004;101:934-9.
71. Kulke MH, Kim H, Stuart K, Clark JW, Ryan DP, Vincitore M et al. A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest 2004;22:353-9.
72. Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 2001;91:1543-8.
73. Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979;2:327-34.
74. Engstrom PF, Lavin PT, Moertel CG, Foisch E, Douglass HO, Jr. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 1984;2:1255-9.
75. Bukowski RM, Johnson KG, Peterson RF, Stephens RL, Rivkin SE, Neilan B et al. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 1987;60:2891-5.
76. Fine R, Fogelman D, Schreibman S. Effective treatment of neuroendocrine tumors with temozolomide and capecitabine. J Clin Oncol 2005;23:4216.
77. Chaudhry A, Papanicolaou V, Oberg K, Heldin CH, Funa K. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res 1992;52:1006-12.
78. Chaudhry A, Oberg K, Gobl A, Heldin CH, Funa K. Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. Anticancer Res 1994;14:2085-91.
79. Terris B, Scoazec JY, Rubbia L, Bregeaud L, Pepper MS, Ruszniewski P et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998;32:133-8.
80. Nilsson O, Wangberg B, Kolby L, Schultz GS, Ahlman H. Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours. Int J Cancer 1995;60:645-51.
81. Krishnamurthy S, Dayal Y. Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in gastrointestinal carcinoids. Am J Surg Pathol 1997;21:327-33.
82. Lankat-Buttgereit B, Horsch D, Barth P, Arnold R, Blocker S, Goke R. Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. Digestion 2005;71:131-40.
83. Hopfner M, Baradari V, Huether A, Schofl C, Scherubl H. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr Relat Cancer 2006;13:135-49.
84. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
85. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients with unresectable neuroendocrine tumors. J Clin Oncol 2005;23:310s.
86. Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 2007;13:234-40.
87. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006;407:597-612.
88. Hobday TJ, Rubin J, Holen K. MCO44h, a phase II trial of sorafenib in patinet with metatatic neuroendocrine tumors (NET) a phase II consortium (P2C) study. J Clin Oncol 2007;25:199s.
89. Hobday TJ, Mahoney M, Erlichman C. Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. J Clin Oncol 2005;23:382S.
90. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95:1148-54.
91. Yao JC, Phan AT, Chang DZ, Jacobs C, Mares JE, Rashid A et al. Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET). J Clin Oncol 2006;24:4042.
92. Xu Y, Ellison C, Martin E, Young D, Campbell J, Vinci L et al. A phase II study of thalidomide in metastatic neuroendocrine tumors. J Clin Oncol 2002;21:30b.
93. Varker KA, Campbell J, Shah MH. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 2008;61:661-8.
94. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-6.
95. Yao JC, Ng C, PM H. Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. J Clin Oncol 2005;23: 16s.
96. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008;26:1316-23.